Highlights

  • Shares of Clarity Pharmaceuticals surged 17.48% in Monday’s trade.
  • Phase II Co-PSMA data showed higher lesion detection rates.
  • Findings to be presented at EAU Congress 2026 in London.

Shares of Clarity Pharmaceuticals Ltd (ASX:CU6) climbed 17.48% to AUD 3.36 at the time of writing on 16 February 2026, marking a daily gain of AUD 0.50. The rally extended the stock’s five-day advance to 13.90%, reflecting renewed investor activity following recent clinical developments.

Over the past month, the stock has edged up 1.20%. However, performance across a broader timeframe remains mixed. Over six months, CU6 has declined 15.15%, while the year-to-date move shows a fall of 9.43%. On a one-year basis, the stock is down 1.18%.

Despite these shorter-term fluctuations, the longer-term trajectory highlights substantial gains. Over the past five years, Clarity Pharmaceuticals’ shares have risen 128.57%, adding AUD 1.89 during that period. The recent spike in price indicates that market participants are reacting to fresh trial data, even as the stock trades below levels seen six months ago.

Phase II Co-PSMA Trial Results Announced
On 16 February 2026, Clarity Pharmaceuticals announced results from its Phase II Co-PSMA investigator-initiated trial evaluating 64Cu-SAR-bisPSMA in patients with recurrent prostate cancer. The study compared the imaging agent directly with standard-of-care 68Ga-PSMA-11.

The head-to-head trial, led by Prof Louise Emmett at St Vincent’s Hospital Sydney, enrolled 50 patients experiencing biochemical recurrence following radical prostatectomy, with PSA levels ranging between 0.2 and 0.75 ng/mL.

Results indicated that 64Cu-SAR-bisPSMA detected more than twice as many lesions per patient compared with 68Ga-PSMA-11. The mean lesions detected per patient were 1.26 versus 0.48, with statistical significance reported at p<0.0001. In total, 63 lesions were identified using next-day 64Cu imaging, compared with 24 lesions using 68Ga imaging.

At the patient level, 78% (39 out of 50) tested positive with 64Cu-SAR-bisPSMA, compared with 36% (18 out of 50) using 68Ga-PSMA-11. The reported true positive rate was 75% for 64Cu imaging versus 39% for 68Ga imaging. Scan outcomes resulted in changes to planned treatment in 44% of patients enrolled in the study.

Presentation at EAU Congress 2026
The study abstract has been accepted for oral presentation at the European Association of Urology Congress 2026 in London. The presentation platform highlights the clinical relevance of the comparative findings in the context of PSMA PET imaging for recurrent prostate cancer.

Management stated that 64Cu-SAR-bisPSMA could potentially become a new standard of care in PSMA PET imaging, particularly for patients with low PSA levels. The company also referenced the USD 2–3 billion PSMA imaging market in outlining the broader commercial landscape.

Clarity Pharmaceuticals’ shares recorded a sharp single-day gain following the release of Phase II Co-PSMA trial data demonstrating higher lesion detection rates compared to standard-of-care imaging. While the stock shows mixed short- to medium-term performance trends, the five-year return remains positive. Market participants are tracking further clinical milestones, including the upcoming presentation at the EAU Congress 2026, as developments continue in the competitive PSMA imaging space.

FAQs

Q1. How did Clarity Pharmaceuticals’ shares perform on 16 February 2026?
The stock rose 17.48% to AUD 3.36, gaining AUD 0.50 in a single session.

Q2. What were the key findings from the Phase II Co-PSMA trial?
64Cu-SAR-bisPSMA detected more lesions per patient than 68Ga-PSMA-11 and showed higher patient-level positivity rates.

Q3. Where will the trial results be presented?
The abstract will be presented at the European Association of Urology Congress 2026 in London.